Department of Biochemistry and Molecular Biology

Chang Gung University Academic Capacity Ensemble

Research directions and laboratory features

Our Functional Proteomics Laboratory integrates functional proteomics with biochemical, molecular, and cell biology approaches to systematically define the regulatory mechanisms connecting nucleocytoplasmic transport, vesicular trafficking, and cancer development. We investigate how organelles communicate through specific proteins and clarify the roles of these pathways in human disease. In translational research, we are building a comprehensive proteomics database from diverse cancer samples to develop biomarkers for precise lung cancer diagnosis and monitoring, advancing personalized medicine. We also study the oncogenic functions of the nucleocytoplasmic transport protein KPNA2, revealing its roles in tumor progression and therapeutic resistance and providing new molecular insights into cancer biology. In the mechanistic studies, we recently discovered that Golgin‑97 has non‑canonical functions and exhibits tumor‑suppressive activity. It operates within a complex regulatory network that integrates intracellular and extracellular signaling, immune responses, and vesicular trafficking. This finding opens new directions for exploring the functions and pathological relevance of Golgi-associated proteins.

The core strengths of our laboratory include:

• Using quantitative proteomics as a platform to bridge basic and clinical research.

• Advancing mechanistic studies while expanding disease-focused applications.

• Establishing integrated research strategies across species and organelles.

Through this interdisciplinary platform, we aim to uncover key mechanisms of cellular transport systems and drive the development of innovative biomarkers and cancer therapies.

Publication

1.          Chiu WY, Wang YH, Lin MC, Lai CC, Yu CJ*, Lee FJ*. Glycerol mediates crosstalk between metabolism and trafficking through the golgin Imh1. Nature Structural & Molecular Biology 2025 Oct;32 (10):1907-1919.

2.          Liu YC, Lin TJ, Chong KY, Chen GY, Kuo CY, Lin YY, Chang CW, Hsiao TF, Wang CL, Shih YC, Yu CJ*. Targeting the ERK1/2 and p38 MAPK pathways attenuates Golgi tethering factor golgin-97 depletion-induced cancer progression in breast cancer. Cell Communication and Signaling 2025, Jan 13;23(1):22.

3.          Hsiao TF, Wang CL, Wu YC, Kuo CY, Lin KW, Chuang WY, Yeh CJ, Wu CC, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ*. Myeloid-derived growth factor-regulated oncogenesis in lung adenocarcinoma is associated with EGFR status and cancer aggressiveness. Journal of Proteome Research 2025 Sep 5;24 (9):4674-4688.

4.          15.     Liao WC, Lin TJ, Liu YC, Wei YS, Chen GY, Feng HP, Chang YF, Chang HT, Wang CL, Chi HC, Wang CI, Lin KH, Ou Yang WT, Yu CJ*. Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1-STAT1 loop in lung adenocarcinoma. Cancer Science 2022 Jan;113(1):205-220.

5.          Hsiao TF, Wang CL, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ*. Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. Clinical Cancer Research 2020 Jul 1;26 (13):3220-3229.